comprehensive -WSS

comprehensive

author：fashion 2025-10-02 21:35:51 - browse：4386

1:43Traders work on the floor of the New York Stock Exchange on July 12, 2023 in New York City.Spencer Platt/Getty Images

As long-standing recession alarms continue to blare from some forecasters, investors don’t appear to hear them.

The S&P 500 this year, when excluding the ten largest companies, stands at single-digit gains.

Looking ahead, Agati and Moya said they expect the stock market to decline over the remainder of the year, ending 2023 with positive but modest returns. The full economic cooling-off effects of central bank rate hikes have yet to take hold, they said, adding that inflation may not return to normal levels as soon as investors hope.

"The rally will stall out here," Moya said.

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

Stoltzfus, however, said there's a "good chance" the stock market will end the year higher than it currently stands.

"We have maintained a fairly bullish posture," he said. "Where the market is trading right now would suggest to us that it has further to go this year."

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Devoted Health’s losses in Medicare Advantage persist

Wikipedia

WSS

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why Novartis is going to walk from its acquisition of MorphoSys

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO: AstraZeneca says CAR

Cano Health’s bankruptcy is a warning for Medicare Advantage

FDA's Pazdur wants cancer trials to range beyond China alone

focus

comprehensive

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

ASCO: AstraZeneca says CAR

Hepatitis C has a cure — but many Americans still lack access to it

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Heart attack and stroke risk calculators need revising

Unique patient identifier: Experts argue the benefits, pitfalls

Medicare details structure of new drug price negotiation program

Letters to First Opinion on caregivers, digital health, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Biogen Aduhelm mess could happen again

hotspot

At ASCO, AstraZeneca reports strong data for breast cancer drug

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Global cancer cases to surge 77% by 2050, WHO report says

With trial win, GSK could get blood cancer drug back on market

340B reform proposal comes out of Senate working group

focus

explore

Wikipedia

hotspot